MARKET

LIFE

LIFE

aTyr Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.240
0.000
0.00%
Opening 09:39 07/10 EDT
OPEN
4.300
PREV CLOSE
4.240
HIGH
4.350
LOW
4.240
VOLUME
4.45K
TURNOVER
--
52 WEEK HIGH
7.62
52 WEEK LOW
2.130
MARKET CAP
39.65M
P/E (TTM)
-0.9323
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average LIFE stock price target is 11.50 with a high estimate of 15.00 and a low estimate of 8.00.

EPS

LIFE News

More
Edited Transcript of LIFE earnings conference call or presentation 12-May-20 9:00pm GMT
Thomson Reuters StreetEvents · 06/22 21:52
aTyr Pharma Presents Preclinical Research Showing NRP2 Antibody Effects in Triple-Negative Breast Cancer at the 2020 AACR Virtual Annual Meeting II
SAN DIEGO, June 22, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a poster and audio presentation at the 20
GlobeNewswire · 06/22 12:00
aTyr Pharma Highlights New Literature Implicating Neuropilin Pathway In SARS-CoV-2 Infection
GlobeNewswire · 06/17 22:01
Dosing underway in aTyr Pharma's ATYR1923 study in COVID-19 patients
Seeking Alpha - Article · 06/15 12:42
aTyr Pharma Announces Dosing of First Patient in Phase 2 Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
GlobeNewswire · 06/15 12:00
Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know
Zacks · 06/12 17:00
Edited Transcript of LIFE earnings conference call or presentation 26-Mar-20 9:00pm GMT
Thomson Reuters StreetEvents · 06/02 10:27
aTyr Pharma to Present Poster at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
SAN DIEGO, May 20, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will present an abstract in a post
GlobeNewswire · 05/20 12:03

Industry

Biotechnology & Medical Research
-0.45%
Pharmaceuticals & Medical Research
-0.26%

Hot Stocks

Symbol
Price
%Change

About LIFE

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.
More

Webull offers kinds of aTyr Pharma Inc stock information, including NASDAQ:LIFE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LIFE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LIFE stock methods without spending real money on the virtual paper trading platform.